Substitute for form 1449A/PTO

PTO/Statute (10-00)

Approved for use through 10/31/2002. OMB 0651-0031*

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1998 repeated to respond to a collection of information unless it contains a valid OWB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 2

	Complete if Known
Application Number	10/028,075
Filing Date	12/21/2001
First Named Inventor	Khan et al.
Group Art Unit	To be assigned 1636
Examiner Name	To be assigned J. Dunston
Attorney Docket Number	2183-5223US

				U.S. PA	TENT DOCUM	ENTS		
		U.S. Pa	U.S. Patent Document		entee or Applicant	Date of Publication of	Pages, Columns, Lines,	Where Relevant
Examiner Initials *	Cite No.1	Number	Kind Code (if known)	² of Cited	of Cited Document	Cited Document MM-DD-YYYY	Passages or F Figures Ap	elevant pear
		0,919,0	504	04	to ot al.	11-20-2001	Duplicate	Citatio
		<u> </u>						
	 	 						
		 					000	
							70.	A PARTIE OF THE PROPERTY OF THE PARTIE OF TH
	i						14	240.
								(PALEAGO
								(E)
		L						
	ļ							
							<u> </u>	}
		L						
	L	ļ				····		
								
			1	1				_1

	FOREIGN PATENT DOCUMENTS							
Examiner	C3-	For	eign Patent D	ocument	Name of Patentee	Date of Publication of	Pages, Columns, Lines,	
Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Te
	 		 					
	ļ_ -	 	 				<u> </u>	
	 	-						
					,			
	<u> </u>	<u> </u>						

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 5 Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through T0/31/2002. OMB 0651-0031

S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no dispons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 2

AUC	Complete if Known
Application Number	10/028,075
Filing Date	12/21/2001
First Named Inventor	Khan et al.
Group Art Unit	To be assigned 1636
Examiner Name	To be assigned J. Dunston
Attorney Docket Number	2183-5223US

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/JD/		CONNELLY et al., Biphasic Regulation of NF-kB Activity Underlies the Pro- and Anti-Inflammatory Actions of Nitric Oxide, The Journal of Immunology, 2001, pp. 3873-81, 166, The American Association of Immunologists, USA.			
/JD/		FRIEDLANDER, Tackling anthrax, Nature, November 8, 2001, pp. 160-61, Vol. 414.			
/JD/		MEDZHITOV, TolHike Receptors and Innate Immunity, Nature Reviews/Immunology, November 2001, pp. 135-45, Vol. 1.			
			_		

	الأواران والمراجع المراجع والمراجع والمراجع المراجع والمراجع والمراجع والمراجع والمراجع والمراجع والمراجع		
Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/028,075

Filing Date December 21, 2001

First Named Inventor Khan et al.

Group An Unit Pobe assigned 1636

Examiner Name To be assigned J. Dunston

 (use as many sheets as necessary)
 Examiner Name
 To be assigned

 Sheet
 1
 of
 2
 Attorney Docket Number
 2183-5223US

U.S. PATENT DOCUMENTS					
Examiner Cite		Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
Initials *	No.'	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
		US-			
		US-	·		
		US-			

		FOREIGN P	ATENT DOCU	MENTS		
Examiner	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
Initials* No.1	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Т*	
		WO 99/99617	11-28-1999	Linamus Universiteit	Duplicate C	itat:
/JD/		WO 97/49721	12-31-1997	University of Maryland		
		<u> </u>				
						
	 	 	 		ļ	
	ļ	 			 	ļ
			 		 	
	 	 	-		 	
	ļ	L]	

Exan Signa	/Jennifer Dunston/ (05/18/2007)	Date Considered		
			·	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/028,075

Filing Date December 21, 2001

First Named Inventor Khan et al.

Group Art Unit To be assigned 1636

Examiner Name To be assigned J. Dunston

Attorney Docket Number 2183-5223US

(use as many sheets as necessary)

Sheet 2 of 2

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Initials * No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/JD/		PCT International Search Report, PCT/NL01/00259, dated December 18, 2001, 3 pages.	_
PCT Int		PCT International Preliminary Examination Report, PCT/NL99/00313, dated July 21, 2000, 6 pages.	
		PCT International Search Report, PCT/EP99/00313, dated November 29, 1999, 3 pages.	
		Lang et al., "Induction of apoptosis in Kaposi's sarcoma spindle cell cultures by the subunits of human chorionic gonadotropin", AIDS 1997, Vol. 11, No. 11, pp.1333-1340.	<u>-</u>
/JD/		Iskandar et al., "Effects of a urinary factor from women in early pregnancy on HIV-1. SIV and associated disease", Nature Medicine, April 1998, Vol. 4, No. 4, pp. 428-434.	
		·	
		·	

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ADEAD Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/028,075

Filing Date December 21, 2001

First Named Inventor Khan et. al.

Group Art Unit 1032 1636

Examiner Name T. McKelvey J. Dunston

(use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket Number 2183-5223US

Examiner Cite Initials * No.	Document Number	Publication Date	Name of Patentee or Applicant of			
		Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/JD/		US- 4,977,244	12-11-1990	Muchmore et al.		
		UG- 5,677,275	10-14-1007	Lunardi lokandar et al.	Duplicate	Citatio
/JD/		US- 5,877,148	03-02-1999	Lunardi-Iskandar et al.		
		US- 5,958,413	09-28-1999	Anagnostopulos et al.		
		US- 5,997,871	12-07-1999	Gallo et al.		
	<u> </u>	US- 6,319,504 B1	11-20-2001	Gallo et al.		
		US- 2003/0049273 A1	03-13-2003	Gallo et al.		
		US- 6,583,109 B1	06-24-2003	Gallo et al.		
		US- 6,596,688 B1	07-22-2003	Gallo et al.		
		US- 6,620,416 B1	09-16-2003	Gallo et al.		-
		US- 2002/0064501	05-30-2002	Khan et al.	<u> </u>	
\sqrt{I}		US- 2002/0041871	04-11-2002	Brudnak		
V		US-5,851,997	12-22-1998	Harris		
/JD/		US- 6,489,296	12-03-2002	Grinnell et al.	1	

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Cite Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Publication Date	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T 6	
/JD/		EP 1 300 418	04-09-2003	Erasmus Universiteit Rotterdam		
		WO 98/35691	08-20-1998	Proscript, Inc.		
		WO 02/085117	10-31-2002	Eisai Co., Ltd.		
		DE 3715662	11-19-1987	The Wellcome Foundation Ltd.		_
		DE 19953339	05-17-2001	Goldham Pharma GmbH		
	١.	WO 96/04008	02-15-1996	Government of the United States		
		WO 97/49373	12-31-1997	University of Maryland Biotechnology Institute		
V		WO 97/49418	12-31-1997	University of Maryland Biotechnology Institute		
/JD/		WO 97/49432	12-31-1997	University of Maryland Biotechnology Institute		

			$\overline{}$
Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Sheet

ADDIMITUTE for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known Application Number 10/028,075 Filing Date December 21, 2001 First Named Inventor Khan et. al. 1632 1636 Group Art Unit T. McKelvey J. Dunston Examiner Name Attorney Docket Number 2183-5223US

	, -	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	_
Examiner Cite No.!		\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
		KANUNGO et al., Advanced Maturation of Heteropneustes Fossilis (Bloch) by Oral Administration of Human Chorionic Gonadotropin, J. Adv. Zool., 1999, pp. 1-5, Vol. 20.	
		ROHRIG et al., Growth-stimulating Influence of Human Chorionic Gonadotropin (hCG) on Plasmodium falciparum in vitro, Zentralblatt Bakt, 1999, pp. 89-99, Vol. 289.	
		TAK et al., NF-kappaB: a key role in inflammatory diseases, J Clin Invest., 2001, pp. 7-11, Vol. 107.	
		TAN et al., The role of activation of nuclear factor-kappa B of rat brain in the pathogenesis of experimental allergic encephalomyelitis, Acta Physiol Sinica, 2003, pp. 58-64, Vol. 55.	
		TOVEY et al., Mucosal Cytokine Therapy: Marked Antiviral and Antitumor Activity, J. Interferon Cytokine Res., 1999, pp. 911-21, Vol. 19.	
$\sqrt{}$		MUCHMORE et al., Immunoregulatory Properties of Fractions from Human Pregnancy Urine: Evidence that Human Chorionic Gonadotropin is not Responsible, The Journal of Immunology, March 1997, pp. 881-86, Vol. 118, No. 3.	
/JD/		MUCHMORE et al., Purification and Characterization of a Mannose-Containing Disaccharide Obtained from Human Pregnancy Urine, Journal of Experimental Medicine, December 1984, pp. 1672-85, Volume 160.	

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	
ColPumero	,	Constacted	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

Examiner Cite Initials * No.1	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
/JD/ =		US-5,380,668	01-10-1995	Негтоп	
1		US- 2003/0186244 A1	10-02-2003	Margus et al.	
		US- 2003/0113733 A1	06-19-2003	Khan et al.	
		US- 2003/0119720 A1	06-26-2003	Khan et al.	
1		US- 2002/0064501 A1	05-30-2002	Khan et al.	
T		US- 2003/0166556 A1	09-04-2003	Khan et al.	
L		US- 2003/0215434 A1	11-20-2003	Khan et al.	
		US- 2003/0219425 A1	11-27-2003	Khan et al.	
		US- 2003/0220257 A1	11-27-2003	Benner et al.	
		US- 2003/0220258 A1	11-27-2003	Benner et al.	
		US- 2003/0220259 A1	11-27-2003	Benner et al.	
		US- 2003/0220260 A1	11-27-2003	Khan et al.	
1		US- 2003/0220261 A1	11-27-2003	Khan et al.	
V^-		US- 2003/0224995 A1	12-04-2003	Khan et al.	
JD/		US- 2004/0013661 A1	01-22-2004	Wensvoort et al.	
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1		Where Relevant Passages or Relevant Figures Appear	T ⁶		
/JD/		WO 03/029292 A2	04-10-2003	Erasmus Universiteit Rotterdam		
	ļ		 			
	 					
			1			
						

Examiner / Jappifor Dunston/ (05/19/2007) Date	
Examiner Signature /Jennifer Dunston/ (05/18/2007) Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

is Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO PADEM

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

JUN 3 0 2006

Complete if Known **Application Number** 10/028,075 December 21, 2001 Filing Date First Named Inventor Khan et al. Group Art Unit 1636 T. McKelvey J. Dunston **Examiner Name**

2183-5223US

(use as many sheets as necessary)

of 2 Sheet Attorney Docket Number

			U.S. PATENT D	OCUMENTS		
F		Document Number	Publication Date	Name of Patentee or Applicant of	D. C. C. L. L. M. D. L. D. L. L. L. D. L.	
Examiner Initials *	Cite No. 1	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Pages, Cohimns, Lines, Where Relevant Passages or Relevant Figures Appear	
/JD/		US-6,727,227	04-27-2004	Khavinson		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

Examiner Initials*	Cite	Foreign Patent Document		Name of Patentee or	Pages, Cohimns, Lines,	
	No.1	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T6
/JD/		WO 01/29067	04-26-2001	Obschestvo S Ogranichennoi Otvetstvennostiju "Klinika Instituta Bioregulyatsii I Gerontologii"		

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) . ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 10/028,075 INFORMATION DISCLOSURE Filing Date December 21, 2001 STATEMENT BY APPLICANT First Named Inventor Khan et al. Group Art Unit 1636 (use as many sheets as necessary) Examiner Name T. McKelvey J. Dunston of 2Attorney Docket Number 2183-5223US

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
/JD/ L		KACHRA et al., "Low Molecular Weight Components but Not Dimeric HCG Inhibit Growth and Down-Regulate AP-1 Transcription Factor in Kaposi's Sarcoma Cells," Endocrinology, 1997, pp. 4038-4041, vol. 138, no. 9.	
		KHAVINSON et al., "Mechanisms Underlying Geroprotective Effects of Peptides," Bulletin of Experimental Biology and Medicine, January 2002, pp. 1-5, Vol. 133, No. 1.	
		KHAVINSON et al., "Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell," Bulletin of Experimental Biology and Medicine, May 2004, pp. 503-506, Vol. 137, No. 5.	
		MOROZOV et al., "Natural and Synthetic Thymic Peptides as Therapeutics for Immune Dysfunction," Int. J. Immunopharmac., 1997, pp. 501-505, Vol. 19, No. 9/10.	
		KHAVINSON et al., "Inductive Activity of Retinal Peptides," Bulletin of Experimental Biology and Medicine, November 2002, pp. 482-484, Vol. 134, No. 5.	
		KHAVINSON et al., "Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects," Bulletin of Experimental Biology and Medicine, January 2004, pp. 78-81, Vol. 137, No. 1.	
		KHAVINSON et al., "Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People," Bulletin of Experimental Biology and Medicine, October 2002, pp. 389-392, Vol. 134, No. 4.	-
		KHAVINSON et al., "Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells," Bulletin of Experimental Biology and Medicine, June 2003, pp. 590-592, Vol. 135, No. 6.	ė
$\sqrt{}$		IVANOV et al., "Hemoglobin as a Source of Endogenous Bioactive Peptides: The Concept of Tissue-Specific Peptide Pool," Biopolymers, 1997, pp. 171-188, Vol. 39.	
/JD/		KHAVINSON et al, Gerontological Aspects of Genome Peptide Regulation, 2005, S. Karger AG, Basel, Switzerland.	

	,		
Examiner	/Jennifer Dunston/ (05/18/2007)	Date]
Signature	7001111101 Bullotolii (00/10/2007)	Considered]

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

stitute of August 1970

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 3

(use as many sheets as necessary)

		Document Number		Name of Patentee or Applicant of	
Examiner Initials •	Cite No.	Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Cited Document	Pages, Cohumns, Lines, Where Relevant Passages or Relevant Figures Appear
/JD/		US-2003/0148955	08-2003	Pluenneke	
		US- 4,427,660	01-1984	Schiffman et al.	
		US- 4,571,336	02-1986	Houck et al.	
		US- 4,753,965	06-1988	Stemerick et al.	
		US- 5,002,961	03-1991	Dage et al.	
		US- 5,223,397	06-1993	Pouletty	
		US- 5,801,193	09-1998	Ojo-Amaize et al.	
		US- 5,942,494	08-1999	Ginsberg et al.	
		US- 5,972,924	10-1999	Keep et al.	
		US- 6,051,596	04-2000	Badger	
		US- 6,075,150	06-2000	Wang et al.	
		US- 6,235,281	05-2001	Stenzel et al.	
		US- 6,310,041	10-2001	Haddox et al.	
Y		US- 6,630,138	10-2003	Gerlitz et al.	
וטני		US- 6,831,057	12-2004	Baldwin et al.	
		US-			

		FOREIGN P		Name of Patentee or	Pages, Columns, Lines,	_
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T6
/JD/		WO 98/34631 A1	08-1998	Thomas Jefferson University		
/JD/		WO 2001/83554 A2	11-2001	Praecis Pharmaceuticals Incorporated et al.		
					,	
					·	

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute (for form 1449A	/РТО				Complete if Known
INEO	Полити	IONI I	D.T.	adition 100	Application Number	10/028,075
				SCLOSURE	Filing Date	December 21, 2001
SIAI	EMEN	LBA	A	PPLICANT	First Named Inventor	Khan et al.
					Group Art Unit	1636
	(use as ma	iny sheets	asi	necessary)	Examiner Name	J. Dunston
Sheet	2		of	3	Attorney Docket Number	2183-5223US

Examiner Initials * Cite No. 1		 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		ABRAHAM, E., "Coagulation Abnormalities in Acute Lung Injury and Sepsis," Am. J. Respir. Cell Mol. Biol., 2000, pp. 401-404, Vol. 22.	
		ADIB-CONQUY et al., "NF-kappaB Expression in Mononuclear Cells in Patients with Sepsis Resembles That Observed in Lipopolysaccharide Tolerance," Am. J. Respir. Crit. Care Med., 2000, pp. 1877-1883, Vol. 162.	
		ARIMA et al., "IL-2-Induced Growth of CD8+ T Cell Prolymphocytic Leukemia Cells Mediated by NF-kappaB Induction and IL-2 Receptor alpha Expression," Leukemia Research, 1998, pp. 265-273, Vol. 22, No. 3.	
		BAEUERLE et al., "Function and Activation of NF-kappaB in the Immune System," Annu. Rev. Immunol., 1994, pp. 141-179, Vol. 12.	
		BETHEA et al., "Traumatic Spinal Cord Injury Induces Nuclear Factor-kappaB Activation," The Journal of Neuroscience, I May 1998, pp. 3251-3260, Vol. 18, No. 9.	
		BODFISH et al., "Treating the Core Features of Autism: Are We There Yet?" Mental Retardation and Developmental Disabilities Research Reviews, 2004, pp. 318-326, Vol. 10.	
		BROWN et al., "Two Forms of NF-kappaB1 (p105/p50) in Murine Macrophages: Differential Regulation by Lipopolysaccharide, Interleukin-2, and Interferon-garma," Journal of Interferon and Cytokine Research, 1997, pp. 295-306, Vol. 17.	
		EMMEL et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation," Science, 22 December 1989, pp. 1617-1620, Vol. 246.	
		EPINAT et al., "Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway," Oncogene, 1999, pp. 6896-6909, Vol. 18.	
\	/	FAUST et al., "Disseminated intravascular coagulation and purpura fulminans secondary to infection," Bailliere's Clinical Haematology, 2000, 179-197, Vol. 13. No. 2.	
/.	JD/	JIMENEZ-GARZA et al., "Early Effects of Modulating Nuclear factor-kappaB Activation on Traumatic Spinal Cord Injury in Rats," Ann. N.Y Acad. Sci., 2005, pp. 148-150, Vol. 1053.	

Examiner	/Jennifer Dunston/ (05/18/2007)	Date	
Signature	,	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Properwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known **Application Number** 10/028,075 INFORMATION DISCLOSURE Filing Date December 21, 2001 STATEMENT BY APPLICANT First Named Inventor Khan et al. **Group Art Unit** 1636 (use as many sheets as necessary) **Examiner Name** J. Dunston 2183-5223115 Attomey Docket Number

	1	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials * Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the ite (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publish city and/or country where published.	
		KIDD et al., "Autism, An Extreme Challenge to Integrative Medicine. Part II: Medical Management," Alternative Medicine Review, 2002, pp. 472-499, Vol. 7, No. 6.	
		KRONFOL et al., "Cytokines and the Brain: Implications for Clinical Psychiatry," Am. J. Psychiatry, May 2000, pp. 683-694, Vol. 157, No. 5.	
		LI et al., "NF-kappaB Regulation in the Immune System," Nature Reviews/Immunology, October 2002, pp. 725-734, Vol. 2.	
		MALEK-AHMADI, P., "Role of Cytokines in Psychopathology: Therapeutic Implications," Drug News Prospects, June 1998, pp. 271-276, Vol. 11, No. 5.	
		MCBEAN et al., "Rodent Models of Global Cerebral Ischemia: A Comparison of Two-Vessel Occlusion and Four-Vessel Occlusion," Gen. Pharmac., 1998, pp. 431-434, Vol. 30, No. 4.	
		MCDONALD et al., "Interleukin-15 (IL-15) Induces NF-kappaB Activation and IL-8 Production in Human Neutrophils," Blood, 15 December 1998, pp. 4828-4835, Vol. 92, No. 12.	
		NEELY et al., "Then and now: Studies using a burned mouse model reflect trends in burn research over the past 25 years," Burns, 1999, pp. 603-609, Vol. 25.	
		SMITH et al., "Recent developments in drug therapy for multiple sclerosis," Multiple Sclerosis, 1999, pp. 110-120, Vol. 5.	
		TRAYSTMAN, R., "Animal Models of Focal and Global Cerebral Ischemia," ILAR Journal, 2003, pp. 85-95, Vol. 44, No. 2.	
$\sqrt{}$		WEINBERGER et al., "Mechanisms Mediating the Biologic Activity of Synthetic Proline, Glycine, and Hydroxyproline Polypeptides in Human Neurophils," Mediators of Inflammation, 2005, pp. 31-38, Vol. 1.	
/JD/		YANG et al., "Increased cortical nuclear factor kappaB (NF-kappaB) DNA binding activity after traumatic brain injury in rats," Neuroscience Letters, 1995, pp. 101-104, Vol. 197.	

Examiner	/Jennifer Dunston/ (05/18/2007)	Date	ì
Signature	(0,70,200,7	Considered	J

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/028,075

Filing Date December 21, 2001

First Named Inventor Khan et al.

Group An Unit 1636

Examiner Name J. Dunston

Attorney Docket Number 2183-5223US

(use as many sheets as necessary)
Sheet 1 of 2

US-US-

U.S. PATENT DOCUMENTS Name of Patentee or Applicant of Document Number Publication Date Pages, Columns, Lines, Where Relevant Examiner Cite Cited Document Initials * No.1 MM-DD-YYYY Passages or Relevant Number - Kind Code2 (if known) Figures Appear JDI US- 4,855,285 08-1989 Stevens US- 5,994,126 11-1999 Steinman et al. US- 6,150,500 11-2000 Salerno US- 2004/0208885 A1 10-2004 Khan et al. US- 6,844,315 01-2005 Khan et al. US- 2005/0037430 A1 02-2005 Khan et al. US-US-US-US US US. US-US-US-US-US-

F	a	FOREIGN P Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Т6
						_
						
	<u> </u>		 			
						_

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 10/028,075 INFORMATION DISCLOSURE Filing Date December 21, 2001 STATEMENT BY APPLICANT First Named Inventor Khan et al. Group Art Unit 1636 (use as many sheets as necessary) **Examiner Name** J. Dunston 2183-5223US Attorney Docket Number

	,	NON PATENT LITERATURE DOCUMENTS	
Initials * No.'		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the iten (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), published city and/or country where published.	
		CUI et al., Am. J. Physiol. Integr. Comp. Physiol., 2004, pp. R699-R709, Vol. 286.	
		DWINNELL et al., Atlas of Diseases of the Kidney, Blackwell Sciences, 1999, pp. 12.1-12.12, Ch. 12.	
		KALNS et al., Biochem Biophys. Res. Comm., 2002, pp. 506-09, Vol. 297.	
		KALNS et al., Biochem. Biophys. Res. Comm., 2002, pp. 41-44, Vol. 292.	
		Merck Index, 17th ed. 1999, pp. 1145-1146, 1841-1848, 2539, 2551.	
		Merriam-Webster Medical Dictionary, 1994, p. 82.	
		MOAYER1 et al., Journal of Clinical Investigation, September 2003, pp. 670-82, Vol. 112, No. 5.	
\overline{V}		NGO et al., The protein folding problem and tertiary structure prediction, 1994, pp. 492-94.	
/JD/		PELLIZZARI et al., FEBS Letters, 1999, pp. 199-204, Vol. 462.	
		·	

Examiner	/Jennifer Dunston/ (05/18/2007)	Date	
Signature		Considered]

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

t of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. PIDENT

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 10/028,075 Application Number December 21, 2001 Filing Date First Named Inventor Khan et al. 1636 Group Art Unit Examiner Name J. Dunston

(use as many sheets as necessary)

Substitute for form 1449A/PTO

of 3 2183-5223US Attorney Docket Number

Examiner Cite Initials • No.	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
	Number - Kind Code ² (if lown)	MM-DD-YYYY		Passages or Relevant Figures Appear	
		US-2003/0148955	08-2003	Pluenneke	
		US- 4,427,660	01-1984	Schiffman et al.	
		US- 4,571,336	02-1986	Houck et al.	
		US- 4,753,986	06-1988	Stemerick et al.	
		US- 5,002,961	03-1991	Dage et al.	
		US- 5,223,397	06-1993	Pouletty	
		US- 5,801,193	09-1998	Ojo-Amaize et al.	
		US- 5,942,494	06-1999	Ginsberg et al.	
		US- 5,972,924	10-1999	Keep et al.	
		US- 6,051,598	04-2000	Badger	
		US- 6,075,150	06-2000	Wang et al.	
		US- 6,235,281	05-2001	Stenzel et al.	
		US- 8,310,041	10-2001	Haddox et al.	
	1	US- 6,630,138	10-2003	Gerlitz et al.	
		US- 6,831,057	12-2004	Baldwin et al.	Duplicate Citati
	1.	US-			
		US-			
	1	US-			

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Cite Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Approximation control Wilder Control and an area		Γ *
		WO 88/34631 A1	08-1998	Thomas Jefferson University		
		WO 2001/83554 A2	11-2001	Praecis Pharmaceuticals Incorporated et al.	Duplicate Ci	tatio

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known 10/028,075 Application Number INFORMATION DISCLOSURE December 21, 2001 Filing Date STATEMENT BY APPLICANT Khan et al. First Named Inventor 1636 Group Art Unit J. Dunston (use as many sheets as necessary) Examiner Name 2183-5223US Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		ASRAHAM, E., "Coagulation Abnormalities in Acute Lung Injury and Sepsis," Am. J. Respir. Cell Mol. Biol., 2000, pp. 401-404, Vol. 22.	
		ADIB-CONOLY et al., "NF-kappaB Expression in Mononuclear Cells in Patients with Sepsis Resembles That Observed in Lipopolysacchands Tolerance," Am. J. Respir. Crit. Care Med., 2000, pp. 1877-1883, Vol. 162.	
		ARIMA et al., "IL-2-Inditated Growth of CD8+ T Cell Prolymphocytic Leukemia Cells Mediated by NF-kappaB Induction and IL-2 Receptor alpha Expression" Leukemia Research, 1998, pp. 265-273, Vol. 22, No. 3.	
		BAEUERLE et al., "Function and Achiention of NF-kappaB in the Immune System," Annu. Rev. Immunol., 1994, pp. 141-179, Vol. 12.	
		BETHEA et al., "Traumatic Spinal Cord Injury Induces Nuclear Factor-kappaB Activation," The Journal of Neuroscience, I May 1998, pp. 3251-3260, Vol. 18, No. 9.	
		BODFISH et al., "Treating the Core Features of Autism: Are We There Yet?" Mental Retardation and Developmental Disabilities Research Reviews, 2004, pp. 318-326, Vol. 10.	
		BROWN et al., "Two Forms of NF-kappaB1 (p105/p50) in Murine Macophages: Differential Regulation by Lipopolysaccharide, Interleukin-2, and Interferon-gamma," Journal of Interferon and Cytokine Research, 1997, pp. 295-306, Vol. 17.	
		EMMEL et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation," Science, 22 December 1989, pp. 1617-1620, Vol. 246.	
		EPINAT et al., "Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway," Oncogene, 1999, pp. 6896-6909, Vol. 18.	
		FAUST et al., "Disseminated intravascular coagulation and purpura fulminans secondary to infection," Bailliers's Clinical Haematology, 2000, 179-197, Vol. 13. No. 2.	
		JIMENEZ-GARZA et al., "Early Effects of Modulating Nuclear factor-kappaB Activation on Traumatic Spinal Cord Injuly in Rats," Ann. N.Y Acad. Sci., 2005, pp. 148-150, Vol. 1053.	

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

fuction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known 10/028,075 INFORMATION DISCLOSURE Application Number December 21, 2001 Filing Date STATEMENT BY APPLICANT Khan et al. First Named Inventor Group Art Unit 1636 J. Dunston (use as many sheets as necessary) **Examiner Name** 2183-5223US Attorney Docket Number

	I	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
Examiner Initials *	ish * No. Number - Kind Code ² (if known) MM-DD-YYYY		Cited Document	Passages or Relevam Figures Appear	
	1	US-4,855,285	08-1989	Stevens	
		US- 5,994,126	11-1999	Steinman et al.	
	1	US- 6,150,500	11-2000	Salemo	
		US- 2004/0208885 A1	10-2004	Khan et al.	
		US- 6,844,315	01-2005	Khan et al.	
		US- 2005/0037430 A1	02-2005	Khan et al.	Duplicate Citatio
		US-			
		US-			
		US-			
		US-	,		
		US-			
	1	US-			

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Cite Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T°
	<u> </u>		· 			
			1			
					ļ	
			ļ		ļ	

	بمساند بيرين والمستوانية والمراجع والمناكمين والمناكمين والمناكمين والمستوانية والمستوانية والمراجع		
Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) . ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Attorney Docket Number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Complete if Known Application Number 10/028,075 Filing Date December 21, 2001 First Named Inventor Khan et al. Group Art Unit 1636 Examiner Name J. Dunston 2183-5223115

(use as many sheets as necessary)

		NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials •	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		СЛ et al., Am. J. Physiol. Integr. Сопр. Physiol., 2004, pp. R699-R709, Vol. 286.	
		DWINNBLL et al., Atlas of Diseases of the Kidney, Blackwell Sciences, 1999, pp. 12.1-12.12, Ch. 12.	
		KALNS et al., Blachem. Biophys. Res. Comm., 2002, pp. 506-09, Vol. 297.	
		KALNS et al., Biochem Riophys. Res. Comm., 2002, pp. 41-44, Vol. 292.	
		Merck Index, 17th ed. 1999, pp. 145-1146, 1841-1848, 2539, 2551.	
		Merriam-Webster Medical Dictionary, 1994, p. 82.	
		MOAYERI et al., Journal of Clinical Investigation September 2003, pp. 670-82, Vol. 112, No. 5.	
		NGO et al., The protein folding problem and tertiary structure prediction, 1994, pp. 492-94.	
		PELLIZZARI et al., FEBS Letters, 1999, pp. 199-204, Vol. 462. Duplicate Citations	

	,		
Examiner	/Jennifer Dunston/ (05/18/2007)	Date	
Signature	/ Common Danielon, (Com 10/2001)	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE rk Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1404/PEOC

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 10/028,075 Application Number Filing Date December 21, 2001 First Named Inventor Khan et. al. 1632 1636 Group Art Unit Examiner Name T. McKelvey J. Dunston Attorney Docket Number 2183-5223US

(use as many sheets as necessary)

Examiner Cite		Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
Initials *	a case	Cited Document	Passages or Relevant Figures Appear		
		OC-4,977,244	12-11-1990	Muchmore et al.	
		US- 5,674,275	10-14-1997	Lunardi-Iskandar et al.	
		US- 5,877,148	03-02-1999	Lunardi-Iskandar et al.	
		US- 5,958,413	09-28-1999	Anagnostopulos et al.	
		US- 5,997,871	12-07-1999	Gallo et al.	
		US- 6,319,504 B1	11-20-2001	Gallo et at.	
		US- 2003/0049273 A1	03-13-2003	Gallo et al.	
		US- 6,583,109 B1	06-24-2000	Gallo et al.	
-		US- 6,596,688 B1	07-22-2003	Gallo et al.	
		US- 6,620,416 B1	09-16-2003	Gallo et al.	
		US- 2002/0064501	05-30-2002	Khan et al.	
		US- 2002/0041871	04-11-2002	Brudisk	
		US-5,851,997	12-22-1998	Harris	
		US- 6,489,296	12-03-2002	Grinnell et al.	Ouplicate Citatio

		FOREIGN P.	ATENT DOCU	IMENTS	•	
Examiner Cite Initials* No.1		Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cohmms, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		EP 1 300 418	04-09-2003	Erasmus Universiteit Rotterdam		
		WO 98/35691	08-20-1998	Proscript, Inc.	<u> </u>	
		WO 02/085117	10-31-2002	Eisai Co., Ltd.		
		DE 3715662	11-19-1987	The Wellcome Foundation Ltd.		
		DE 19953339	05-17-2001	Goldham Pharma GmbH		
		96/04008	02-15-1996	Government of the United States		
		97/49373	12-31-1997	University of Maryland Biotechnology Institute		
		97/49418	12-31-1997	University of Maryland Biotechnology Institute		
		97/49432	12-31-1997	University of Maryland Biotechnology Institute	Duplicate Ci	catio

(Solitorial (Solitorial)	Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	
--------------------------	-----------------------	---------------------------------	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Patentwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Application Number 10/028,075 INFORMATION DISCLOSURE Filing Date December 21, 2001 STATEMENT BY APPLICANT First Named Inventor Khan et. al. Group Art Unit 1632 1636 (use as many sheets as necessary) Examiner Name T. McKelvey J. Dunston Sheet of Attorney Docket Number 2183-5223US

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials •	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т2
		CHRISTMAN et al., Nuclear factor kappaB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intens Care Med, 1998, pp. 1131-38, Vol. 24.	
		JYONOUCHI engl., Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression, J Neuroim., 2001, pp. 170-79, Vol. 120.	
		KANUNGO et al., Advanced Maturation of Heteropneustes Fossilis (Bloch) by Oral Administration of Human Chorionic Gonadotropin, J. Adv. Zool., 1999, pp. 1-5, Vol. 20.	
		ROHRIG et al., Growth-stimulating Influence of Human Chorionic Gonadotropin (hCG) on Plasmodium falciparum in vitro, Zentralblant Bakt, 1999, pp. 89-99, Vol. 289.	
		TAK et al., NF-kappaB: a key role in inflammatory diseases, Slin Invest., 2001, pp. 7-11, Vol. 107.	
		TAN et al., The role of activation of nuclear factor-kappa B of rat brain in the pathogenesis of experimental allergic encephalomyelitis, Acta Physiol Sinica, 2003, pp. 58-64, Vol. 55.	
		TOVEY et al., Mucosal Cytokine Therapy: Marked Antiviral and Antitumor Activity, J. Interferon Cytokine Res., 1999, pp. 911-21, Vol. 19.	
		MUCHMORE et al., Immunoregulatory Properties of Fractions from Human Pregnancy Urine: Evidence that Human Chorionic Gonadotropin is not Responsible, The Journal of Immunology, March 1997, pp. 881-86, Vol. 118, No. 3.	
		MUCHMORE et al., Purification and Characterization of a Mannose-Containing Disaccharide Obtained from Human Pregnancy Urine, Journal of Experimental Medicine, December 1984, pp. 1672-85, Volume 160.	

			Duplicate	Citations
Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

+

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEFARTMENT OF COMMERCE
ork persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Short N / Let No I

_	Complete if Known
Application Number	10/028,075
Filing Date	December 21, 2001
First Named Inventor	Khan et al.
Group Art Unit	1636
Examiner Name	J. Dunston
Attorney Docket Number	2183-5223US

<u>-</u>		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
		KEDD et al., "Autism, An Extreme Challenge to Integrative Medicine. Part II: Medical Management," Alternative Medicine Review 2002, pp. 472-499, Vol. 7, No. 6.	
		KRONFOL et al., "Cytokines and the Brain: Implications for Clinical Psychiatry," Am. J. Psychiatry, May 2000, pp. 683-694, Vol. 157, No. 5.	
		LI et al., "NF-kappaB Regulation in the Immune System," Nature Reviews/Immunology, October 2002, pp. 725-734, Vol. 2.	
		MALEK-AHMADI, P., "Role of Cytokines in Psychopathology: Therapeutic Implications," Drug News Prospects, June 1998, pp. 271-276, Vol. 11, No. 5.	
		MCBEAN et al., "Rodent Models of Global Cerebral Ischemia: A Comparison of Two-Vessel Occlusion and Four-Vessel Occlusion," Gen. Pharmac., 1998, pp. 431-434, Vol. 30, No. 4.	
		MCDONALD et al., "Interleukin-15 (IL-15) Induces NF-kappaB Activation and IL-8 Production in Human Neutrophils," Blood, 15 December 1998, pp. 4828-4835, Vol. 92, No. 12.	
		NEELY et al., "Then and now: Studies using a burned mouse model reflect trends in burn research over the past 25 years," Burns, 1999, pp. 603-609, Vol. 25.	
		SMITH et al., "Recent developments in drug therapy for multiple sclerosis," Multiple Sclerosis, 1999, pp. 110-120, Vol. 5.	
		TRAYSTMAN, R., "Animal Models of Focal and Global Cerebral Ischemia," ILAR Journal, 2003, pp. 85-95, Vol. 44, No. 2.	•
		WEINBERGER et al., "Mechanisms Mediating the Biologic Activity of Synthetic Proline, Glycine, and Hydroxyproline Polypeptides in Human Neurophils," Mediators of Inflammation, 2005, pp. 31-38, Vol. 1.	
		YANG et al., "Increased cortical nuclear factor kappaB (NF-kappaB) DNA binding activity after traumatic brain injury if cats," Neuroscience Letters, 1995, pp. 101-104, Vol. 197.	

			Duplicate	Citations
Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 1 Applicant is to place a check mark here if English language Translation is attached.

or use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

DEC 11

INFORMATION DISCLOSURE ATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known **Application Number** 10/028,075 Filing Date 12/21/2001 Khan et al. First Named Inventor To be assigned 1636 **Group Art Unit** Dunston **Examiner Name** Te-be-assigned J. 2183-5223US Attorney Docket Number

Special			 U.S. PATENT DOCUI	MENTS	
Elass	C32	U.S. Patent Doc	 Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Releva
Examiner Initiats *	Cite No.1	Number Kind (of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
		0,840,504	Callo et al.	11 20 2001	Duplicate Citat
				· · · · · · · · · · · · · · · · · · ·	

				FOREIG	N PATENT DOCU	IMENTS		
Examiner Cite	Cha	For	eign Patent D		Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Office ³	Number ⁴	Kind Code ⁶ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Te
				· · ·				
		 				ļ		
		<u> </u>						
							· · · · · · · · · · · · · · · · · · ·	
								<u> </u>
		L						
		T	I					l

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known
INFORMATION BIGGLOCUES	. Application Number	10/028,075
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	12/21/2001
STATEMENT BY APPLICANT	First Named Inventor	Khan et al.
DEC . E	Group Art Unit	To be assigned 1636
DEC Yusamas Barry sheets as necessary)	Examiner Name	To be assigned J. Dunston
Sheet 2 , / 9 of 2 14	Attorney Docket Number	2183-5223US

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		CONNELLY et al., Biphasic Regulation of NF-kB Activity Underlies the Pro- and Anti-Inflammatory Actions of Nitric Oxide, The Journal of Formunology, 2001, pp. 3873-81, 166, The American Association of Immunologists, USA.			
•		FRIEDLANDER, Tackling anthrax, Nature, November 6, 2001, pp. 160-61, Vol. 414.			
		MEDZHITOV, Toli-like Receptors and Irrnate Immunity, Nature Reviews/Immunology, November 2001, pp. 135-45, Vol. 1.			
		Duplicate Citations			

Examiner	//	Date	
Signature	/Jennifer Dunston/ (05/18/2007)	Considered	·

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 10/028,075 Application Number Filing Date December 21, 2001 First Named Inventor Khan et al. Group Art Unit 1636 **Examiner Name** T. McKelvey Dunston

(use as many sheets as necessary)

10 Sheet

of 3

Attorney Docket Number	2183-5223US

	т		U.S. PATENT D	T	1	
Examiner Cite Initials No.	Cita	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines	Where Relevant
		Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear	
-	U3-0,721,227	04-27-2004	- Khavinson	Duplicate	Citatio	
		US-				
		US-				
		US-				
		US-				
-		US-		1		
		US-				
		US-				
		US-				
		US-				
	1	US-				
		US-				
		US-				
	1	US-			1	
		US-			<u> </u>	
	1	US-		1		
		US-	· · · · · · · · · · · · · · · · · · ·		 	

Examiner Cite Initials* No.1	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
		Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T٩
		WO 01/00067	04-20-2001	Obschestvo S Ogranichennoi Otvetstvennostiiu "Klinika Instituta	Duplicate	
				Bioregulyatsii I Gerontologii	Citation	

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known
TAMODA A MICAL DICCI OCUDE	Application Number	10/028,075
INFORMATION DISCLOSURE	Filing Date	December 21, 2001
STATEMENT BY APPLICANT	First Named Inventor	Khan et al.
	Group Art Unit	1636
(use as many sheets as necessary)	Examiner Name	T. McKelvey J. Dunston
Sheet 2 II of 14	Attorney Docket Number	2183-5223US

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		KACHRA et al., "Low Molecular Weight Components but Not Dimeric HCG Inhibit Growth and Down-Regulate AP-1 Transcription Factor in Kaposi's Sarcoma Cells," Endocrinology, 1997, pp. 4038-4041, vol. 138, no. 9.	
		KHAVINSON et al., "Mechanisms Underlying Geroprotective Effects of Peptides," Bulletin of Experimental Biology and Medicine, January 2002, pp. 1-5, Vol. 133, No. 1.	
		KHAVINSON et al., "Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell," Bulletin of Experimental Biology and Medicine, May 2001, pp. 503-506, Vol. 137, No. 5.	
		MOROZOV et al., "Natural and Syntheth Thymic Peptides as Therapeutics for Immune Dysfunction," Int. J. Immunopharmac., 1997, pp. 501-505, Vol. 19, No. 9/10.	
		KHAVINSON et al., "Inductive Activity of Retinal Postides," Bulletin of Experimental Biology and Medicine, November 2002, pp. 482-484, Vol. 134, No. 5.	
		KHAVINSON et al., "Effects of Short Peptides on Lymphocyte Commatin in Senile Subjects," Bulletin of Experimental Biology and Medicine, January 2004, pp. 78-81, Vol. 137, No. 1.	
		KHAVINSON et al., "Effects of Livagen Peptide on Chromatin Activation in Symphocytes from Old People," Bulletin of Experimental Biology and Medicine, October 2002, pp. 389-392, Vol. 134, No. 4.	
		KHAVINSON et al., "Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells," Bulletin of Experimental Biology and Medicine, June 2003, pp. 590-592, Vol. 135, No. 6.	
-		IVANOV et al., "Hemoglobin as a Source of Endogenous Bioactive Peptides: The Concept of Tissue-Specific Peptide Pool," Biopolymers, 1997, pp. 171-188, Vol. 39.	
		KHAVINSON et al, Gerontological Aspects of Genome Peptide Regulation, 2005, S. Karger AG, Basel, Switzerland.	,
	 	Duplicate Citat	on

			$\overline{}$
Examiner	/Jennifer Dunston/ (05/18/2007)	Date Considered	}
Signature	· · · · · · · · · · · · · · · · · · ·	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

 Complete if Known

 Application Number
 10/028,075

 Filing Date
 December 21, 2001

 First Named Inventor
 Khan et al.

 Group Art Unit
 To be assigned
 1636

 Examiner Name
 To be assigned
 J. Dunston

(use as many sheets as necessary)

there 12 of No.

14	Attorney Docket Number	2183-5223US

		·	U.S. PATENT I	OCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
	No.1	Number - Kind Code' (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
	İ	US-			
		US-	,		
		US-			
-		US-			
		US-			
		US-			

		FOREIGN P	ATENT DOCU	MENTS		
Examiner Cite No. 1	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	<u> </u>
	No.'	Country Code' - Number' - Kind Code' (If known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T*
		WO 99/59617	11-25-1999	Erasmus Universiteit		
		WO 97/49721	12-31-1997	University of Minyland D1	plicate Cita	tion
	ļ					
	ļ					<u> </u>
	<u> </u>		 			
			-			

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) . ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

4 INFORMATION DISCLOSURE ATEMENT BY APPLICANT

(use as many sheets as necessary)

	Complete if Known
Application Number	10/028,075
Filing Date	December 21, 2001
First Named Inventor	Khan et al.
Group Art Unit	To be assigned 1636
Examiner Name	To be assigned J. Dunston
Attorney Docket Number	2183-5223US

	т	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	, ···
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		PCT International Search Report, PCT/NL01/00259, dated December 18, 2001, 3 pages.	
		PCT International Preliminary Examination Report, PCT/NL99/00313, dated July 21, 2000, 6 pages.	
		PCT International Search Report, PCT/EP99/00313, dated November 29, 1999, 3 pages.	
		Lang et al., "Induction of apoptosis in Kaposi's sarcoma spindle cell cultures by the cubunits of human chorionic gonadotropin", AIDS 1997, Vol. 11, No. 11, pp.1333-1340.	
		Iskandar et al., "Effects of a urinary factor from women in early pregnancy on HIV-1. SIV and associated disease", Nature Medicine, April 1998, Vol. 4, No. 4, pp. 428-434.	
		Duplicate Citations	
-			
			·

Signature /Jennifer Dunston/ (05/18/2007) Considered	Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	
--	-----------------------	---------------------------------	--------------------	--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of \ Sheet

Complete if Known				
Application Number	10/028,075	_		
Filing Date	December 21, 2001			
First Named Inventor	Khan et al.			
Group Art Unit	1636			
Examiner Name	T. McKelvey J. Dunston			
Attorney Docket Number	2183-5223US			

			U.S. PATENT D	OCUMENTS	·	
Examiner Initials *	Cite No.	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, \ Passages or Re Figures App	levant
	 	VS-5,380,668	01-10-1995	Herron		
		US- 2803/0186244 A1	10-02-2003	Margus et al.		
-	†——	US- 2003/01\3733 A1	06-19-2003	Khan et al.		
	†	US- 2003/0119720 A1	06-26-2003	Khan et al.		
		US- 2002/0064501 A1	05-30-2002	Khan et al.		
		US- 2003/0166556 A1	09-04-2003	Khan et al.		
		US- 2003/0215434 A1	11-20-2003	Khan et al.		
		US- 2003/0219425 A1	11-97-2003	Khan et al.	<u> </u>	
		US- 2003/0220257 A1	11-27-2063	Benner et al.	<u></u>	
	<u> </u>	US- 2003/0220258 A1	11-27-2003	Benner et al.		
		US- 2003/0220259 A1	11-27-2003	Benner et al.		
		US- 2003/0220260 A1	11-27-2003	Khan et al.		
		US- 2003/0220261 A1	11-27-2003	Khan et al.		
		US- 2003/0224995 A1	12-04-2003	Khan et al		
		US- 2004/0013661 A1	01-22-2004	Wensvoort et al.	Duplicate	<u>Citatio</u>
		US-		`		
		US-				
		US-				
		US-				
	T	US-				

		FUREIGN P	ATENT DOCU	MENTS		
Examiner Cite Initials* No.1	Cin	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines,	ı
		Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY		Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 03/030303 A3	04 10 2003	Erasmus Universiteit	Duplicate Ci	tatio
	<u> </u>					
	 	-				
	 					
			I			İ

			_
Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	J

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional) . See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.